Category: Treatments & Protocols

If you live with peripheral neuropathy, you already know the standard script: a prescription for gabapentin or pregabalin, a suggestion to control your blood sugar, and a shrug when neither one gives your feet back to you. The Regenerve protocol starts from a different premise — that burning, tingling, and numbness are not the disease but the alarm, and that the goal of treatment is to repair the terrain the nerves live in, not simply to mute the signal they are sending. This article walks through the logic of that protocol, the science behind each stage, and an honest accounting of what is proven, what is emerging, and what remains investigational.

Why symptom suppression alone falls short

The medications most people are handed — the gabapentinoids (gabapentin, pregabalin) and certain antidepressants (duloxetine, amitriptyline) — work by dampening the transmission of pain signals in the nervous system. They are legitimate tools, and for many patients they take the edge off. But two facts are rarely explained at the pharmacy counter.

First, the benefit is often partial. Across the neuropathic-pain literature, only a minority of patients achieve substantial (50% or greater) pain relief from any single oral agent, and many discontinue because of side effects like sedation, dizziness, weight gain, and cognitive fog. Second — and more fundamentally — none of these drugs touch the process that is damaging the nerve. They quiet the alarm while the fire keeps burning. That is why patients so often describe climbing to the maximum dose and still waking at 3 a.m. with their feet on fire.

The Regenerve premise is that lasting change requires addressing why the nerve is failing, then giving it the conditions to recover.

Metabolic sovereignty: treating the terrain, not just the nerve

Dr. Padda uses the phrase “metabolic sovereignty” to describe the underlying philosophy: your nerves cannot heal in a hostile environment. A nerve fiber is one of the most metabolically demanding structures in the body. It must maintain an electrical gradient along its entire length, transport nutrients and mitochondria from the cell body out to the nerve endings, and constantly repair its insulating myelin. Starve it of oxygen, poison it with the byproducts of high blood sugar, or drain its energy supply, and it will misfire, retract, and eventually die back — starting at the longest, most distant fibers, which is why symptoms begin in the toes and feet.

So before any regenerative step makes sense, the terrain has to be assessed and corrected: blood sugar and glycation, micronutrient status, circulation, inflammatory drivers, and mechanical contributors. This is the diagnostic backbone that a companion article — “The 11 Hidden Drivers Your Doctor Missed” — explores in depth. The protocol below assumes that this root-cause work is happening in parallel; the regenerative tools are not a substitute for it.

Stage one: quiet the overfiring nerve

When a damaged nerve becomes chronically hyperexcitable, it fires pain even in the absence of a real threat. One way to interrupt that is to “defunctionalize” the overactive pain fibers at the skin level using high-concentration capsaicin.

The 8% capsaicin patch (marketed as Qutenza) is the most evidence-backed piece of this stage. It works on the TRPV1 receptor — the same receptor that makes chili peppers feel hot — which sits on the small pain-sensing C-fibers in the skin. A single controlled application overstimulates and then reversibly “switches off” those endings, reducing their pain signaling for weeks to months. This is not folk medicine: the U.S. FDA approved the 8% capsaicin patch for postherpetic neuralgia in 2009 and, after the pivotal STEP trial led by Dr. David Simpson, for painful diabetic peripheral neuropathy of the feet in 2020. In the controlled data, a single 30-minute treatment produced modest but statistically significant reductions in daily pain, with the main side effect being temporary application-site burning, and — importantly — no deterioration in patients’ ability to sense sharp, warm, cold, or vibration stimuli. A separate 52-week safety study (PACE) supported repeated treatment without functional or neurological harm.

An honest caveat belongs here, because it is where marketing often overreaches: the established benefit of capsaicin is pain relief, not proven nerve regrowth. Whether repeated capsaicin treatment can help damaged nerve fibers actually regenerate is a genuine scientific question currently under formal investigation (including a randomized disease-modification trial out of Cambridge), not a settled fact. Regenerve uses capsaicin to create a window of reduced pain and reduced nociceptor overactivity — a window in which the repair-focused steps have room to work.

Stage two: support structural repair with orthobiologics

Once the fire is calmer and the terrain is being corrected, the protocol turns to helping the tissue rebuild. This is where orthobiologics enter — biological materials intended to deliver growth factors and signaling molecules to injured tissue. In the Regenerve protocol these include platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMAC), both derived from the patient’s own blood or marrow.

The rationale is grounded in real biology. Platelets are packed with growth factors — including nerve growth factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and platelet-derived growth factor — that orchestrate healing, angiogenesis (new blood-vessel formation), and, in laboratory and animal models, peripheral nerve regeneration. BMAC additionally supplies a mesenchymal cell population that can modulate inflammation.

Here transparency is essential, and Regenerve’s material is careful about it: the use of PRP and BMAC for peripheral nerve repair is an emerging, largely investigational application. The strongest evidence to date comes from preclinical models and small clinical series, not large randomized trials, and these therapies are not FDA-approved specifically for peripheral neuropathy. Presented honestly, they are a mechanism-driven, patient-derived intervention with encouraging early signals and an incomplete evidence base — which is exactly why they belong in a physician-directed, individualized plan with realistic expectations, not a one-size-fits-all promise.

Stage three: restore the cellular power plant

Even a structurally intact nerve cannot function if its mitochondria — the energy generators inside each cell — are failing. Chronic hyperglycemia, toxins, and nutrient deficiencies all converge on mitochondrial dysfunction, and Dr. Michael Brownlee’s landmark work showed that overproduction of mitochondrial superoxide is a unifying mechanism behind the tissue damage of diabetes. Repairing the wiring without restoring the power supply leaves the job half done.

The protocol therefore incorporates mitochondrial support. This ranges from well-established repletion of the cofactors nerves depend on — the B vitamins, alpha-lipoic acid, and CoQ10 among them — to more advanced, targeted agents. SS-31 (elamipretide) is a mitochondria-targeted peptide designed to stabilize cardiolipin in the inner mitochondrial membrane and improve energy production; it is a real and actively studied compound, but it remains investigational and is not an FDA-approved neuropathy treatment. As with the orthobiologics, the honest framing is that the mitochondrial-support layer combines proven nutritional science with newer, still-experimental tools, selected case by case.

Why sequence matters

The order is deliberate. Correcting the terrain first means the body is no longer actively re-injuring the nerve. Calming the overfiring pain fibers next creates a period of reduced pain and reduced nociceptor chaos. Delivering repair signals and restoring mitochondrial energy last gives the nerve both the instructions and the fuel to recover during that window. Reverse the order — try to “regenerate” a nerve that is still being starved and glycated every day — and you are building on sand.

What to expect as a patient

Peripheral nerves repair slowly, on the order of about a millimeter a day at best, so this is a months-long process measured in gradual change, not an overnight fix. A realistic plan begins with evaluation and diagnostics to map which drivers are active, sets expectations honestly, and adjusts over time based on response. Some patients experience meaningful improvement; results vary by individual and by how advanced the nerve loss is at the start. The earlier the terrain is corrected, the more nerve there is to save.

Frequently asked questions

Key takeaways

• Standard drugs mute the pain signal but do not repair the nerve; partial relief and side effects are common.
• The Regenerve protocol treats the terrain first, then calms overfiring nerves, then supports structural and mitochondrial repair.
• The 8% capsaicin patch is FDA-approved for painful diabetic neuropathy of the feet and provides real, if modest, pain relief; nerve-regrowth claims remain under investigation.
• Orthobiologics (PRP, BMAC) and mitochondrial peptides (SS-31) are biologically rational but investigational for neuropathy, and belong in an individualized plan.
• Nerve repair is slow; earlier intervention preserves more function.

Medically reviewed by Gurpreet Singh Padda, MD — Board certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine. Last reviewed July 2026.

This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary. Do not start, stop, or change any medication or treatment without consulting your physician. Ready to start? Take the free Nerve Damage Score or call/text (314) 886-5902.

References

1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820.
2. Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study (STEP). J Pain. 2017;18(1):42–53.
3. U.S. FDA. Qutenza (capsaicin) 8% topical system — approval for neuropathic pain associated with diabetic peripheral neuropathy of the feet. 2020.
4. Vinik AI, et al. Capsaicin 8% patch repeat treatment plus standard of care in painful diabetic peripheral neuropathy: 52-week open-label safety study (PACE). BMC Neurol. 2016;16:251.
5. Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the 8% capsaicin patch. Br J Anaesth. 2011;107(4):490–502.
6. Sánchez M, et al. Platelet-rich plasma and peripheral nerve regeneration (review of preclinical and early clinical evidence).
7. Szeto HH. First-in-class cardiolipin-protective compound (SS-31/elamipretide) as a therapeutic agent for mitochondrial dysfunction. Br J Pharmacol. 2014.

Note: References 6–7 point to real bodies of work but should be matched to specific, current citations at publication. PRP/BMAC and SS-31 applications to peripheral neuropathy are investigational.

There is a treatment for neuropathic foot pain that is FDA-approved, non-opioid, non-systemic, and applied in a doctor’s office in under an hour — and yet many patients living with burning feet have never been offered it. It is the high-concentration 8% capsaicin patch. This article explains how it works, what the clinical evidence genuinely shows, why it often takes more than one treatment to see the full benefit, and how it fits into a repair-focused protocol. It also draws a careful line between what is proven and what is still being studied — because that distinction is exactly what “mainstream medicine missed” conversations tend to blur.

A note on numbers, up front

You may have seen a very high success figure attached to this protocol. In the interest of honesty: the controlled clinical trials of the 8% capsaicin patch show modest but statistically significant pain relief, not near-universal cure. Any higher real-world success rate reported by an individual clinic reflects that clinic’s own patient population, protocol, and outcome definition — it is a practice observation, not a figure from the randomized trials, and it should be understood that way. What follows sticks to the published science, then explains where clinical experience extends beyond it.

The receptor that makes chili peppers hot

Capsaicin is the compound that gives chili peppers their heat. It acts on a specific sensor on pain-sensing nerve endings called the TRPV1 receptor (transient receptor potential vanilloid 1). TRPV1 is the same receptor that responds to noxious heat — which is why capsaicin literally feels hot.

Low-dose capsaicin creams (0.025–0.075%) available over the counter provide mild, temporary relief and must be applied several times a day. The prescription 8% patch is a different order of magnitude — roughly a hundredfold more concentrated — and is designed to do something the creams cannot: temporarily defunctionalize the overactive pain fibers.

Defunctionalization: turning down an alarm that won’t stop

In chronic neuropathy, the small C-fibers in the skin become pathologically hyperexcitable. They fire pain signals continuously, even without a real stimulus — the alarm is stuck on. A single, controlled 30-minute application of the 8% patch delivers enough capsaicin to overstimulate those TRPV1-bearing endings and then reversibly quiet them. The nerve endings retract and stop transmitting their runaway pain signals; over the following weeks and months they gradually recover. Crucially, controlled studies found this happens without degrading normal sensation — patients retained their ability to feel sharp, warm, cold, and vibration stimuli.

Because the treatment is topical and non-systemic, it sidesteps the sedation, dizziness, and cognitive fog that limit oral neuropathic-pain drugs. The main side effect is temporary burning and redness at the application site, which is why the patch is applied in a clinical setting, often with skin pre-treatment for comfort.

What the evidence shows

The 8% patch first earned FDA approval in 2009 for postherpetic neuralgia (the lingering nerve pain after shingles). In 2020, on the strength of the pivotal STEP trial led by Dr. David Simpson, the FDA extended approval to painful diabetic peripheral neuropathy of the feet. In STEP, a single 30-minute treatment produced a statistically significant reduction in average daily pain compared with placebo. A separate 52-week study (PACE) confirmed that repeated treatments were well tolerated over a full year, with no worsening of sensory function.

This is the honest headline: the patch reliably and safely reduces pain for a meaningful share of patients, and it can be repeated approximately every three months.

Why persistence matters

One reason patients — and sometimes physicians — give up too soon is that they expect a single patch to do everything. The data and clinical experience both suggest the benefit often builds across successive cycles. Each treatment quiets the overfiring fibers again and extends the window of reduced pain. For a chronic condition that took years to develop, expecting resolution from one application is unrealistic; the protocol is designed around repeated, spaced treatments.

The investigational frontier: can it help nerves regrow?

Here is where the science is genuinely exciting but not yet settled. Because capsaicin causes nerve endings to retract and then regenerate, researchers have asked whether repeated treatment might not just relieve pain but actually encourage healthier re-innervation of the skin — in other words, whether it could be disease-modifying. A randomized trial in the United Kingdom is formally testing exactly this question in diabetic neuropathy.

Until that kind of study reports, the responsible position is: the 8% patch is proven for pain relief, and its potential to modify the underlying nerve damage is a promising hypothesis under active investigation. Regenerve’s approach uses the pain-relief window the patch creates as the foundation for the repair-focused steps — orthobiologics and mitochondrial and metabolic support — that aim at the nerve itself. Those regenerative components, as covered in the protocol article, are themselves emerging and individualized rather than guaranteed.

Who is a candidate

The patch is used for localized neuropathic pain, classically in the feet for diabetic neuropathy and in the affected area for postherpetic neuralgia. Suitability depends on a physician’s evaluation of the pain distribution, skin integrity, and overall picture. As with any treatment, it works best as part of a plan that also addresses the root drivers of the neuropathy rather than as a standalone fix.

Frequently asked questions

Key takeaways

• The 8% capsaicin patch is FDA-approved for painful diabetic neuropathy of the feet (2020) and postherpetic neuralgia (2009).
• It works by reversibly quieting overfiring TRPV1 pain fibers, without degrading normal sensation, and without systemic side effects.
• Trial evidence supports real but modest pain relief; benefit often builds across repeated treatments.
• Whether it can help nerves regenerate is a legitimate, still-unproven hypothesis under study.
• It works best inside a plan that also treats the neuropathy’s root causes.

Medically reviewed by Gurpreet Singh Padda, MD — Board certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine. Last reviewed July 2026.

This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary. Do not start, stop, or change any treatment without consulting your physician. Take the free Nerve Damage Score or call/text (314) 886-5902.

References

1. Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study (STEP). J Pain. 2017;18(1):42–53.
2. U.S. FDA. Qutenza (capsaicin) 8% topical system — approval for painful diabetic peripheral neuropathy of the feet. 2020; original PHN approval 2009.
3. Vinik AI, et al. Capsaicin 8% patch repeat treatment plus standard of care in painful diabetic peripheral neuropathy: 52-week open-label safety study (PACE). BMC Neurol. 2016;16:251.
4. Anand P, Bley K. Topical capsaicin for pain management: mechanisms of action of the 8% capsaicin patch. Br J Anaesth. 2011;107(4):490–502.
5. Abrams RMC, et al. A critical review of the capsaicin 8% patch for diabetic peripheral neuropathy of the feet. Expert Rev Neurother. 2021.